Experiences with
Ibrutinib2,003 public posts
Want to take advantage of all our features? Just log in!
or
EU Panel Backs Expanded Indication of Ibrutinib Combos in CLL
More here inc clinical trial data that supported this decision: https://www.onclive.com/web-exclusives/eu-panel-backs-expanded-indication-of-ibrutinib-combos-in-cll--and-waldenstrom-macroglobulinemia
Jackie
Phase 2 study of acalabrutinib in ibrutinib intolerant patients with relapsed/refractory CLL
The ORR was 77% with the Median PFS not reached.
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.7530
The previous report was in 2016 when Justasheet1 posted about Acalabrutinib
https://healthunlocked.com/cllsupport/posts/134578076/acalabrutinib-safe-effective-in-ibrutinib-intolerant-cll-sll
Clinical trial results & reviews of new treatments for CLL written in easy to understand terms
id=31288
-
Here is a sample of the Ibrutinib and Venetoclax write up:
[i] Combining ibrutinib and venetoclax for first-time treatment of chronic lymphocytic leukemia
-
In a nutshell
This study wanted to research if the combination therapy of ibrutinib (Imbruvica) and venetoclax (Venclexta) was effective
The CLL Society Tribune: full of research, news, advice, art and sharing
Shanafelt, the lead on the ECOG trial that showed the superiority of Ibrutinib over FCR in nearly all frontline settings, plus wonderful sharing from patients and caregivers and so much more. Please take a look.
Stay strong. We are all in this together
Brian
Dr. Shadman on Fixed Durations of Treatment in CLL
[i]"Last year, many patients would likely opt for a chemoimmunotherapy regimen as opposed to an oral drug like ibrutinib (Imbruvica) because it is a fixed duration of treatment, says Shadman.